Atossa Therapeutics (NASDAQ: ATOS) furnishes updated corporate presentation

Rhea-AI Filing Summary

Atossa Therapeutics, Inc. reported that it has made an updated corporate presentation available as of September 26, 2025. The presentation is furnished as an exhibit to this report under a Regulation FD disclosure item, meaning it is intended to share information broadly with the market.

The company notes that this material is being furnished, not filed, so it is not subject to certain liability provisions of the federal securities laws and is not automatically incorporated into other SEC filings. The exhibit is identified as a corporate presentation dated September 26, 2025.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

False000148803900014880392025-09-262025-09-26

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 26, 2025

Atossa Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-35610	26-4753208
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
10202 5th Avenue NE, Suite 200
Seattle, Washington				98125
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (206) 588-0256

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check th e appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.18 par value		ATOS		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

Item 7.01 Regulation FD Disclosure

On September 26, 2025, Atossa Therapeutics, Inc. (the “Company”) made available an updated corporate presentation, which is attached to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.

The information in this Current Report on Form 8-K, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing

.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit Number		Description of Exhibit
99.1		Corporate Presentation, dated September 26, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Atossa Therapeutics, Inc.
Date:	September 26, 2025	By:	/s/ Steven C. Quay
			Steven C. Quay, M.D., Ph.D. Chairman, President and Chief Executive Officer

FAQ

What did Atossa Therapeutics (ATOS) disclose in this 8-K?

Atossa Therapeutics disclosed that it made an updated corporate presentation available and furnished it as an exhibit under a Regulation FD disclosure item.

What is included as an exhibit in Atossa Therapeutics’ 8-K?

The filing includes Exhibit 99.1, a Corporate Presentation dated September 26, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Is the Atossa Therapeutics corporate presentation considered filed with the SEC?

No. The company states the information in this report and the exhibit is furnished, not filed, so it is not subject to certain liability provisions and is not automatically incorporated into other SEC filings.

Under which item of Form 8-K did Atossa Therapeutics provide this information?

The information is provided under Item 7.01, Regulation FD Disclosure, which is used for broadly sharing information with the market.

Who signed this Atossa Therapeutics 8-K?

The report was signed on behalf of Atossa Therapeutics, Inc. by Steven C. Quay, M.D., Ph.D., who is the Chairman, President and Chief Executive Officer.

Does this Atossa Therapeutics 8-K contain new financial statements?

No. The 8-K lists exhibits under Item 9.01 but does not provide new financial statements; it focuses on furnishing the updated corporate presentation.